STRYKER CORP
SYKAPI behind this page
SYK Q2 2025 request
Playground key active
/api/financials?ticker=SYK&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 6,022 | 5,422 | +11.1% |
Show Product Lines breakouts |
|||
| Endoscopy · MedSurg and Neurotechnology: | 742 | 623 | +19.1% |
| Endoscopy · MedSurg and Neurotechnology: | 157 | 145 | +8.3% |
| Endoscopy · MedSurg and Neurotechnology: | 899 | 768 | +17.1% |
| Hips · Orthopaedics: | 283 | 261 | +8.4% |
| Hips · Orthopaedics: | 183 | 167 | +9.6% |
| Hips · Orthopaedics: | 466 | 428 | +8.9% |
| Instruments · MedSurg and Neurotechnology: | 621 | 564 | +10.1% |
| Instruments · MedSurg and Neurotechnology: | 147 | 134 | +9.7% |
| Instruments · MedSurg and Neurotechnology: | 768 | 698 | +10.0% |
| Knees · Orthopaedics: | 460 | 433 | +6.2% |
| Knees · Orthopaedics: | 180 | 169 | +6.5% |
| Knees · Orthopaedics: | 640 | 602 | +6.3% |
| Medical · MedSurg and Neurotechnology: | 840 | 763 | +10.1% |
| Medical · MedSurg and Neurotechnology: | 150 | 145 | +3.4% |
| Medical · MedSurg and Neurotechnology: | 990 | 908 | +9.0% |
| Neuro Cranial - Interventional Spine | 129 | 98 | +31.6% |
| Neuro Cranial · MedSurg and Neurotechnology: | 507 | 418 | +21.3% |
| Neuro Cranial · MedSurg and Neurotechnology: | 109 | 96 | +13.5% |
| Neuro Cranial · MedSurg and Neurotechnology: | 616 | 514 | +19.8% |
| Other Orthopedics - Enabling Technologies | 34 | 31 | +9.7% |
| Other · Orthopaedics: | 131 | 124 | +5.6% |
| Other · Orthopaedics: | 52 | 43 | +20.9% |
| Other · Orthopaedics: | 183 | 167 | +9.6% |
| Spinal Implants · Orthopaedics: | 5 | 54 | -90.7% |
| Spinal Implants · Orthopaedics: | 5 | 178 | -97.2% |
| Trauma and Extremities · Orthopaedics: | 702 | 610 | +15.1% |
| Trauma and Extremities · Orthopaedics: | 255 | 222 | +14.9% |
| Trauma and Extremities · Orthopaedics: | 957 | 832 | +15.0% |
| Vascular · MedSurg and Neurotechnology: | 268 | 127 | +111.0% |
| Vascular · MedSurg and Neurotechnology: | 230 | 200 | +15.0% |
| Vascular · MedSurg and Neurotechnology: | 498 | 327 | +52.3% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: | 3,771 | 3,215 | +17.3% |
| MedSurg and Neurotechnology: · Non Us | 793 | 720 | +10.1% |
| MedSurg and Neurotechnology: · Operating Segments | 3,771 | 3,215 | +17.3% |
| MedSurg and Neurotechnology: · US | 2,978 | 2,495 | +19.4% |
| Orthopaedics · Operating Segments | 2,251 | 2,207 | +2.0% |
| Orthopaedics: | 2,251 | 2,207 | +2.0% |
| Orthopaedics: · Non Us | 675 | 655 | +3.1% |
| Orthopaedics: · US | 1,576 | 1,552 | +1.5% |
Show Geography breakouts |
|||
| Non Us | 1,468 | 1,375 | +6.8% |
| US | 4,554 | 4,047 | +12.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 6,022 | 5,422 | +11.1% |
| Cost of Revenue | 2,181 | 2,006 | +8.7% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 1,414 | 1,287 | +9.9% |
| Orthopaedics · Operating Segments | 599 | 576 | +4.0% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -3 | -10 | +70.0% |
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -3 | -10 | +70.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,013 | 1,863 | +8.1% |
| Gross Profit | 3,841 | 3,416 | +12.4% |
| Research & Development | 407 | 363 | +12.1% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 246 | 194 | +26.8% |
| Orthopaedics · Operating Segments | 127 | 136 | -6.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 373 | 330 | +13.0% |
| Selling, General & Administrative | 2,079 | 1,831 | +13.5% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 984 | 775 | +27.0% |
| Orthopaedics · Operating Segments | 743 | 756 | -1.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,727 | 1,531 | +12.8% |
| Amortization Of Intangible Assets | 187 | 155 | +20.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 187 | 155 | +20.6% |
| Asset Impairment Charges | 55 | 16 | +243.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 55 | 16 | +243.8% |
| Operating Expenses | 2,728 | 2,365 | +15.3% |
| Operating Income | 1,113 | 1,051 | +5.9% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 1,069 | 903 | +18.4% |
| Orthopaedics · Operating Segments | 678 | 634 | +6.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,747 | 1,537 | +13.7% |
| Non-Operating Income (Expense) | -97 | -53 | -83.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -9 | -22.2% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -8 | -37.5% |
| Income Before Taxes | 1,016 | 998 | +1.8% |
| Income Tax Expense (Benefit) | 132 | 173 | -23.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | -3 | +66.7% |
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -3 | -5 | +40.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -2 | -2 | 0.0% |
| Net Income | 884 | 825 | +7.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 884 | 825 | +7.2% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 1,113 | 1,051 | +5.9% |
| EPS (Basic) | 2.32 | 2.17 | +6.9% |
| EPS (Diluted) | 2.29 | 2.14 | +7.0% |
| Wtd Avg Shares (Basic) | 382.2 | 381 | +0.3% |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 4.2 | 4.4 | -4.5% |
| Wtd Avg Shares (Diluted) | 386.4 | 385.4 | +0.3% |
| Common Stock Dividends Per Share Declared | 0.84 | 0.8 | +5.0% |
| Comprehensive Income | 531 | 847 | -37.3% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract | 29 | 28 | +3.6% |
| Foreign Exchange Contract · Cost Of Sales | 3 | 10 | -70.0% |
| Foreign Exchange Contract · Other Nonoperating Income Expense | 15 | 10 | +50.0% |
Show Derivative Instruments Gain Loss By Hedging Relationship breakouts |
|||
| Net Investment Hedging · Other Nonoperating Income Expense | 11 | 8 | +37.5% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,375 | 1,874 | +26.7% |
| Available For Sale Securities Debt Securities Current | 89 | 83 | +7.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 89 | 83 | +7.2% |
| Fair Value Inputs Level2 · Asset Backed Securities | 50 | 48 | +4.2% |
| Fair Value Inputs Level2 · Certificates Of Deposit | 2 | 5 | -60.0% |
| Fair Value Inputs Level2 · US Treasury Securities | 37 | 29 | +27.6% |
| Accounts Receivable | 3,918 | 3,622 | +8.2% |
| Inventory Raw Materials And Supplies Net Of Reserves | 1,305 | 1,163 | +12.2% |
| Inventory Work In Process Net Of Reserves | 436 | 380 | +14.7% |
| Inventory Finished Goods Net Of Reserves | 3,548 | 3,501 | +1.3% |
| Inventory | 5,289 | 5,044 | +4.9% |
| Prepaid Expense Current | 1,332 | 1,022 | +30.3% |
| Total Current Assets | 13,003 | 11,645 | +11.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,702 | 3,318 | +11.6% |
| Goodwill | 19,183 | — | — |
Show Business Acquisition breakouts |
|||
| Inari | 3,187 | — | — |
| Deferred Tax Assets | 1,375 | 1,606 | -14.4% |
| Other Non-Current Assets | 3,106 | 2,790 | +11.3% |
| Total Assets | 46,331 | — | — |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 26,909 | — | — |
| Orthopaedics · Operating Segments | 17,865 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 1,557 | — | — |
| Operating Segments | 44,774 | — | — |
| Operating Lease Right-of-Use Assets | 551 | 510 | +8.0% |
| Other Assets | |||
| Property Plant And Equipment Gross | 7,272 | 6,622 | +9.8% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 3,570 | 3,304 | +8.1% |
| Intangible Assets Net Excluding Goodwill | 5,962 | 4,363 | +36.6% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,442 | 1,304 | +10.6% |
| Employee Related Liabilities Current | 1,075 | 887 | +21.2% |
| Accrued Income Taxes Current | 91 | 334 | -72.8% |
| Dividends Payable Current | 321 | 305 | +5.2% |
| Other Liabilities Current | 2,608 | 2,001 | +30.3% |
| Debt Current | 1,751 | — | — |
| Total Current Liabilities | 7,288 | 6,926 | +5.2% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,829 | — | — |
| Accrued Income Taxes Noncurrent | 395 | 350 | +12.9% |
| Other Non-Current Liabilities | 2,628 | 1,965 | +33.7% |
| Total Liabilities | 25,140 | 19,368 | +29.8% |
| Operating Lease Liabilities | 389 | 379 | +2.6% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 38 | 38 | 0.0% |
| Additional Paid In Capital Common Stock | 2,492 | 2,305 | +8.1% |
| Retained Earnings | 19,423 | 17,774 | +9.3% |
| Accumulated Other Comprehensive Income | -762 | — | — |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 21,191 | 19,762 | +7.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 6 | -27 | +122.2% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 34 | 38 | -10.5% |
| Accumulated Other Comprehensive Income | -762 | -355 | -114.6% |
| Accumulated Translation Adjustment | -802 | -366 | -119.1% |
| Additional Paid In Capital | 2,492 | 2,305 | +8.1% |
| Common Stock | 38 | 38 | 0.0% |
| Retained Earnings | 19,423 | 17,774 | +9.3% |
| Total Liabilities & Equity | 46,331 | 39,130 | +18.4% |
| Land Buildings And Improvements Gross | 1,736 | 1,685 | +3.0% |
| Machinery And Equipment Gross | 5,536 | 4,937 | +12.1% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 214 | 210 | +1.9% |
| Stock-Based Compensation | 133 | 133 | 0.0% |
| Sale Of Inventory Stepped Up To Fair Value At Acquisition | 99 | 9 | +1000.0% |
| Deferred Income Taxes | 176 | -31 | +667.7% |
| Change in Accounts Receivable | 257 | 103 | +149.5% |
| Change in Inventory | -226 | -230 | +1.7% |
| Increase Decrease In Accounts Payable Trade | -269 | -205 | -31.2% |
| Increase Decrease In Accrued Liabilities | -116 | -653 | +82.2% |
| Increase Decrease In Accrued Income Taxes Payable | -610 | -284 | -114.8% |
| Increase Decrease In Other Operating Capital Net | -279 | -155 | -80.0% |
| Net Cash from Operations | 1,361 | 837 | +62.6% |
| Depreciation & Amortization | 750 | 709 | +5.8% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 115 | 110 | +4.5% |
| Orthopaedics · Operating Segments | 202 | 213 | -5.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 79 | 78 | +1.3% |
| Operating Segments | 317 | 323 | -1.9% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -4,814 | -334 | -1341.3% |
| Payments To Acquire Marketable Securities | -27 | -32 | +15.6% |
| Proceeds From Maturities Prepayments And Calls Of Shortterm Investments | 750 | — | — |
| Proceeds From Sale And Maturity Of Marketable Securities | 32 | 31 | +3.2% |
| Capital Expenditures | -306 | -319 | +4.1% |
| Proceeds From Sales Of Business Affiliate And Productive Assets | 165 | — | — |
| Other Investing Activities | -40 | 30 | -233.3% |
| Net Cash from Investing | -4,240 | -525 | -707.6% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 2 | — | — |
| Proceeds From Issuance Of Long Term Debt | 2,979 | — | — |
| Repayments Of Long Term Debt | -650 | -600 | -8.3% |
| Payments Of Dividends | -641 | -609 | -5.3% |
| Tax Withholding for Share Compensation | -115 | -127 | +9.4% |
| Proceeds From Payments For Other Financing Activities | -30 | -48 | +37.5% |
| Net Cash from Financing | 1,545 | -1,384 | +211.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 57 | -25 | +328.0% |
| Net Change in Cash | -1,277 | -1,097 | -16.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,375 | 1,874 | +26.7% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.